Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CDKN2A loss
Therapy Palbociclib
Indication/Tumor Type head and neck cancer
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CDKN2A loss head and neck cancer sensitive Palbociclib Phase II Actionable In a Phase II trial (TAPUR), Ibrance (palbociclib) treatment led to a disease control rate (DCR) of 40% (11/28), objective response rate (ORR) of 4% (1/28, 1 partial response), median progression-free survival (mPFS) of 11 weeks and median overall survival (mOS) of 42 weeks in patients with heavily pretreated head and neck cancer harboring CDKN2A alterations, and a DCR of 13% (5/40), ORR of 5% (2/40), mPFS of 8 weeks, and mOS of 26 weeks in patients with advanced solid tumors (PMID: 39413339; NCT02693535). 39413339
PubMed Id Reference Title Details
(39413339) Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. Full reference...